Literature DB >> 12687551

Pathogenic T cells in murine lupus exhibit spontaneous signaling activity through phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways.

Florin Niculescu1, Phuong Nguyen, Teodora Niculescu, Horea Rus, Violeta Rus, Charles S Via.   

Abstract

OBJECTIVE: To determine the activation status of two cytoplasmic signaling pathways, phosphatidylinositol 3-kinase (PI 3-kinase) and the mitogen-activated protein kinase (MAPK) family.
METHODS: We studied the pathogenic CD4+ T cells that drive disease in the parent-into-F(1) mouse model of lupus-like chronic graft-versus-host disease (GVHD). We determined immunoprecipitated kinase activity for PI 3-kinase and MAPK members (Raf-1, extracellular signal-regulated kinase 1 [ERK-1], c-Jun N-terminal kinase 1 [JNK-1], and p38 MAPK) from either unfractionated splenocytes or purified donor CD4+ T cells. Uninjected normal mice served as negative controls, and acute GVHD mice served as positive controls.
RESULTS: Compared with negative controls, unfractionated splenocyte kinase activity from chronic GVHD mice was significantly increased for PI 3-kinase and JNK-1, but not for Raf-1, p38 MAPK, or ERK-1. Increased PI 3-kinase and JNK-1 activity was also seen in acute GVHD splenocytes, as was increased Raf-1 and p38 MAPK activity. The pattern of increased PI 3-kinase and JNK-1 activity seen in unfractionated chronic GVHD splenocytes was also seen in isolated donor, but not host, CD4+ T cells from chronic GVHD mice, indicating that donor CD4+ T cell signaling activity accounted for at least a portion of the activity observed in unfractionated splenocytes. Increased ERK-1 activity was not seen in either donor or host CD4+ T cells. This pattern of cytoplasmic signaling pathway in donor CD4+ T cells was associated with increased T cell receptor membrane signaling activation (Lck and Fyn phosphorylation) and increased transcription activation (phosphorylation of inhibitor of nuclear factor kappaB), confirming the biologic significance of these observations.
CONCLUSION: The pathogenic T cells driving disease in this murine model exhibit activation in the form of spontaneous cytoplasmic signaling pathway activity that can be detected without in vitro restimulation and involves a T cell-specific (PI 3-kinase) and a nonspecific stress/cytokine pathway (JNK-1). These results raise the possibility that a full characterization of the signaling pathways active in pathogenic lupus T cells might lead to new therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12687551     DOI: 10.1002/art.10900

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

Review 1.  T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens.

Authors:  Syamal K Datta; Li Zhang; Luting Xu
Journal:  J Mol Med (Berl)       Date:  2005-01-04       Impact factor: 4.599

Review 2.  Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.

Authors:  Andras Perl
Journal:  Nat Rev Rheumatol       Date:  2015-12-24       Impact factor: 20.543

3.  Dual roles of immunoregulatory cytokine TGF-beta in the pathogenesis of autoimmunity-mediated organ damage.

Authors:  Vijay Saxena; Douglas W Lienesch; Min Zhou; Ramireddy Bommireddy; Mohamad Azhar; Thomas Doetschman; Ram Raj Singh
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

4.  The Parent-into-F1 Model of Graft-vs-Host Disease as a Model of In Vivo T Cell Function and Immunomodulation.

Authors:  R A Puliaev; I A Puliaeva; A E Ryan; C S Via
Journal:  Curr Med Chem Immunol Endocr Metab Agents       Date:  2005-12-01

5.  Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus.

Authors:  Tianfu Wu; Xiangmei Qin; Zoran Kurepa; Kirthi Raman Kumar; Kui Liu; Hasna Kanta; Xin J Zhou; Anne B Satterthwaite; Laurie S Davis; Chandra Mohan
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

6.  c-Jun N-Terminal Kinase in Inflammation and Rheumatic Diseases.

Authors:  Monica Guma; Gary S Firestein
Journal:  Open Rheumatol J       Date:  2012-09-07

Review 7.  The pathology of T cells in systemic lupus erythematosus.

Authors:  Anselm Mak; Nien Yee Kow
Journal:  J Immunol Res       Date:  2014-04-23       Impact factor: 4.818

8.  Dysregulation of Signaling Pathways Due to Differentially Expressed Genes From the B-Cell Transcriptomes of Systemic Lupus Erythematosus Patients - A Bioinformatics Approach.

Authors:  S Udhaya Kumar; D Thirumal Kumar; R Siva; C George Priya Doss; Salma Younes; Nadin Younes; Mariem Sidenna; Hatem Zayed
Journal:  Front Bioeng Biotechnol       Date:  2020-04-30

9.  Establishment and characterization of induced pluripotent stem cells (iPSCs) from central nervous system lupus erythematosus.

Authors:  Maria Teresa De Angelis; Gianluca Santamaria; Elvira Immacolata Parrotta; Stefania Scalise; Michela Lo Conte; Sara Gasparini; Edoardo Ferlazzo; Umberto Aguglia; Clara Ciampi; Antonella Sgura; Giovanni Cuda
Journal:  J Cell Mol Med       Date:  2019-09-19       Impact factor: 5.310

10.  A novel NF-κB inhibitor, DHMEQ, ameliorates pristane-induced lupus in mice.

Authors:  Huiqing Qu; Weihua Bian; Yanyan Xu
Journal:  Exp Ther Med       Date:  2014-05-19       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.